

**Publikationsübersicht 2016  
zum Jahresbericht Onkologie 2016  
der Vinzenz Gruppe**

<b>Ordensklinikum Linz Barmherzige Schwestern</b>	<b>2</b>
<b>Chirurgie</b>	<b>2</b>
<b>Gynäkologie</b>	<b>3</b>
<b>Interne I</b>	<b>4</b>
<b>Molekularbiologie</b>	<b>8</b>
<b>Nuklearmedizin</b>	<b>10</b>
<b>Pathologie</b>	<b>11</b>
<b>Urologie</b>	<b>12</b>
<b>Sankt Josef Krankenhaus Wien</b>	<b>13</b>
<b>Gesamtübersicht</b>	<b>13</b>

(Status: 26.06.2017. Zukünftige Ergänzungen möglich.)

## Ordensklinikum Linz Barmherzige Schwestern

### Chirurgie

Mayer F, Niebuhr H, Lechner M, Dinnewitzer A, Köhler G, Hukauf M, Fortelny RH, Bittner R, Köckerling F. When is mesh fixation in TAPP-repair of primary inguinal hernia repair necessary? The register-based analysis of 11,230 cases. *Surgical Endoscopy* 2016 Oct; 30(10):4363-71. doi: 10.1007/s00464-016-4754-8. PMID: 26886454

Köhler G, Lechner M, Mayer F, Köckerling F, Schrittwieser R, Fortelny RH, Adolf D, Emmanuel K. Self-Gripping Meshes for Lichtenstein Repair. Do We Need Additional Suture Fixation? *World Journal of Surgery* 2016 Feb; 40(2):298-308. doi: 10.1007/s00268-015-3313-0. PMID: 26546187

Antoniou SA, Köhler G, Antoniou GA, Muysoms FE, Pointner R, Granderath FA. Meta-analysis of randomized trials comparing nonpenetrating vs mechanical mesh fixation in laparoscopic inguinal hernia repair. *The American Journal of Surgery* 2016 Jan; 211(1):239-249.e2. doi: 10.1016/j.amjsurg.2015.06.008. Review. PMID: 26316363

Weitzendorfer M, Tschoner A, Schwaiger Ch, Wundsam H, O Spaun G, Emmanuel K, Koch OO. Pepsin Determination in Saliva and Oropharyngeal pH - Monitoring for the Diagnosis of Gastroesophageal Reflux Disease in Patients With Primary Extra-Esophageal Symptoms *Gastroenterology* 2016 Apr

Mayer F, Niebuhr H, Lechner M, Dinnewitzer A, Köhler G, Hukauf M, Fortelny RH, Bittner R, Köckerling F. When is mesh fixation in TAPP-repair of primary inguinal hernia repair necessary? The register-based analysis of 11,230 cases. *Surgical Endoscopy* 2016 Feb 17. [Epub ahead of print] PMID: 26886454

Koch OO, Antoniou SA. Advances in diagnosing GERD: Which examinations should be performed before interventional therapy? *European Surgery* 2016 Jul;

## Gynäkologie

Rezniczek GA, Jüngst F, Jütte H, Tannapfel A, Hilal Z, Hefler LA, Reymond MA, Tempfer CB. Dynamic changes of tumor gene expression during repeated pressurized intraperitoneal aerosol chemotherapy (PIPAC) in women with peritoneal cancer. *BMC Cancer*. 2016 Aug; 19;16:654. doi: 10.1186/s12885-016-2668-4.

Hilal Z, Rezniczek GA, Tettenborn Z, Hefler LA, Tempfer CB. Efficacy of Monsel Solution After Cervical Biopsy: A Randomized Trial. *Journal of Lower Genital Tract Disease* 2016 Oct; 20(4):312-6. doi: 10.1097/LGT.0000000000000234.

Hilal Z, Mavrommati G, Foerster C, Rezniczek GA, Hefler LA, Tempfer CB. Spray Versus Forced Coagulation in Large Loop Excision of the Transformation Zone: A Randomized Trial. *Journal of Lower Genital Tract Disease*. 2016 Apr; 20(2):169-73. doi: 10.1097/LGT.0000000000000177.

Natter C, Polterauer S, Pils S, Castillo-Tong DC, Zeilinger R, Heinze G, Hefler L, Grimm C. Association of -463G/A MPO gene polymorphism and risk of cervical intraepithelial neoplasia. *Archives of Gynecology and Obstetrics* 2016 Apr; 293(4):865-9. doi: 10.1007/s00404-015-3869-9.

## Interne I

Malli T, Buxhofer-Ausch V, Rammer M, Erdel M, Kranewitter W, Rumpold H, Marschon R, Deutsch-bauer S, Simonitsch-Klupp I, Valent P, Muellner-Ammer K, Sebesta C, Birkner T, Webersinke G. Functional characterization, localization, and inhibitor sensitivity of the TPR-FGFR1 fusion in 8p11 myeloproliferative syndrome. *Genes Chromosomes Cancer*. 2016 Jan; 55(1):60-8. doi: 10.1002/gcc.22311. PubMed PMID: 26391436.

Fridrik MA, Jaeger U, Petzer A, Willenbacher W, Keil F, Lang A, Andel J, Burgstaller S, Krieger O, Oberaigner W, Sihorsch K, Greil R. Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma A randomised phase-III study from the Austrian Cancer Drug Therapy Working Group (Arbeitsgemeinschaft Medikamentöse Tumortherapie AGMT) (NHL-14). *European Journal of Cancer* 58 2016 May; 112-121

Greil R, Obrtlíkova, Smolej L, Kozak T, Steurer M, Andel J, Burgstaller S, Mikuskova E, Gercheva L, Nösslinger T, Papajik T, Ladicka M, Girschikofsky M, Hrubisko M, Jäger U, Fridrik M, Pecherstorfer M, Kralikova E, Burcoveanu C, Spasov E, Jurkovicova J, Petzer A, Mihaylov G, Raynov J, Oexle H, Zabernigg A, Flochova E, Palasthy S, Stehlikova O, Doubek M, Altenhofer P, Pleyer L, Melchardt T, Klingler A, Mayer J, Egle A. Rituximab Maintenance versus Observation Alone in Patients with Chronic Lymphocytic Leukaemia who Respond to First- or Second-line Rituximab-containing Chemoimmunotherapy – Final Results of the AGMT CLL-8a Maintenance Trial. *Lancet Haematology* 2016 Jul; 3(7):e317-29. doi: 10.1016/S2352-3026(16)30045-X.

Mela Osorio MJ, Giere I, Fernandez I, Pavlovsky MA, Remaggi G, Sackmann MF, Intile D, Pavlovsky C. Outcome of Long-Term Imatinib in Patients With Chronic Myeloid Leukemia After 10 years of Treatment and Predictive Factors to Achieve Deep Molecular Response. *European Journal of Hematology*; ID: EJM-2016-55-(2821)

Sliwa T, Beham-Schmid C, Burgstaller S, Buxhofer-Ausch V, Gastl G, Geissler K, Krauth M, Krippel P, Lang A, Petzer A, Wöhrer S, Wölfler A, Gisslinger H. Consensus Report; Austrian recommendations for the management of primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (post-PV MF) and postessential thrombocythemia myelofibrosis (post-ET MF): an expert statement

Doleschal B, Rödhammer T, Tsybrovskyy O, Aichberger KJ, Lang F. Disseminated Histoplasmosis: A Challenging Differential Diagnostic Consideration for Suspected Malignant Lesions in the Digestive Tract Case Reports. *Gastroenterology* 2016; 10:653-660

Burgstaller S, Stauder R, Kuehr T, Lang A, Machherndl-Spandl S, Mayrbaeurl B, Noesslinger T, Petzer A, Valent P, Greil R, Thaler J. A phase I study of lenalidomide in patients with chronic myelomonocytic leukaemia (CMML) – AGMT\_CMML\_1 *Haematologica* 2016 Oct; (Ref. 158105)

Sliwa T, Beham-Schmid C, Burgstaller S, Buxhofer-Ausch V, Gastl G, Geissler K, Krauth M, Krippel P, Lang A, Petzer A, Wöhrer S, Wölfler A, Gisslinger H  
Austrian recommendations for the management of primary myelofibrosis, postpolycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis: an expert statement. *Wiener klinische Wochenschrift, online 2016 Dez*; doi 10.1007/s00508-016-1120-8

- **Abstracts:**

Kühr T, Ploner F, Greil R, Petzer A, Girschikofsky M, Wilthoner K, Fridrik M, Eisterer W, Tschmelitsch J, Lang A, Zitt M, Andel J, Baur M, Lang F, Pötscher M, Zauner D. Analyse des Österreichischen Registers für Gastrointestinale Stromatumore. *Österreichische Gesellschaft für Hämatologie Frühjahrstagung 2016*; Poster Klinische Studien K27

Springer A, Hammer J, Winkler E, Track C, Huppert R, Böhm A, Kasparu H, Weltermann A, Aschauer G, Petzer AL, Putz E, Altenburger A, Gruber R, Moser K, Wiesauer K, Geinitz H. Total body irradiation with volumetric modulated arc therapy: Dosimetric data and first clinical experience. *Radiation Oncology 2016*; doi: 10.1186/s13014-016-0625-7

Rammer M, Webersinke G, Haitzchi-Petnehazy S, Bauer E, Hackl H, Charoentong P, Trajanoski Z, Malli T, Steinmair M, Petzer AL, Rumpold H.  
Stage specific miRNA expression in colon cancer "Oral best submitted Abstract", Poster Onkologie P28. *Österreichische Gesellschaft für Hämatologie Frühjahrstagung 2016*

Burghofer J, Kranewitter W, Weitzendorfer M, Marschon R, Rammer M, Alibegovic V, Rumpold H, Petzer AL, Webersinke G. Circulating cell-free DNA in tumor patients "Oral best submitted Abstract", Poster Onkologie P29. *Österreichische Gesellschaft für Hämatologie Frühjahrstagung 2016*

Doleschal B, Rodhammer T, Tsybrovskyy O, Lang F. Suspect malignant oral ulcers – stigmata of disseminated fungal disease. *10. Österr. Infektionskongress, Saalfelden, 2016 Apr*

Hütter-Krönke ML, Benner A, Döhner K, Krauter J, Weber D, Moessner M, Köhne CH, Hors HA, Schmidt-Wolf IG, Rummel M, Götze K, Koller E, Petzer AL, Salwender H, Fiedler W, Kirchen H, Haase D, Kremers S, Theobald M, Matzdorff AC, Ganser A, Döhner H, Schlenk RF. Salvage therapy with high-dose cytarabine and mitoxantrone in combination with alltrans retinoic acid and gemtuzumab ozogamicin in acute myeloid leukemia refractory to first induction therapy. *Haematologica, 2016 Jul*; 101(7):839-45 doi:10.3324/haematol.2015.141622. Epub

Rinnerthaler G, Gampenrieder S, Voskova D, Petzer A, Hubalek M, Petru E, Hartmann B, Andel J, Balic M, Ulmer H, Melchardt T, Mlineritsch B, Greil R.  
Capecitabine in combination with bendamustine in pretreated women with HER2negative metastatic breast cancer: efficacy results of a phase II trial (AGMT MBC-6). *ASCO Annual Meeting 2016*; Abstract #1032

Popper U, Klambauer G, Praher P, Findling R, Webersinke G, Kranewittter W, Hochreiter S, Petzer A, Bodenhofer U, Rumpold H. Assessing intratumor heterogeneity and evolutionary distance in exome sequencing of colon cancer. *ASCO GI 2016*; Abstract # 590, Poster Session C Board # E17

Popper U, Klambauer G, Praher P, Findling R, Webersinke G, Kranewittter W, Hochreiter S, Petzer A, Bodenhofer U, Rumpold H. *Assessing intratumor heterogeneity and evolutionary distance in exome sequencing of colon cancer*. World Congress on Gastrointestinal Cancer, Barcelona, 29 JUN-2 JUL 2016

Petzer A, Herndlhofer S, Weltermann A, Sliwa T, Schmidt S, Greil R, Wölfler A, Wiesholzer M, Dormann C, Thaler J, Tinchon C, Ruckser R, Lang A, Hänig J, Winiger I, Muenchmeier N, Sperr WR. *R-EFFECT: Eine multizentrische, retrospektive Untersuchung des Einflusses des frühen Ansprechens auf das Langzeit-Überleben in der klinischen Praxis der CML-Therapie in Österreich / R-EFFECT: A multicenter, retrospective evaluation of CML therapy in Austria assessing the impact of early treatment response on patient outcomes in a real-life setting*. Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie (DÖSGHO) 2016, Leipzig, Abstract-Referenz-Nummer A-813-0011-00408, P213

Rinnerthaler G, Gampenrieder S, Voskova D, Petzer A, Hubalek M, Petru E, Hartmann B, Andel J, Balic M, Ulmer H, Melchardt T, Mlineritsch B, Greil R. *Capecitabine in combination with bendamustine in pretreated women with HER2negative metastatic breast cancer: efficacy results of a phase II trial (AGMT MBC-6)*. *Annals of Oncology*, Vol. 27, 2016, Supplement 6, 74, Abstract 239P (ESMO 2016)

Steger GG, Petru E, Haslbauer F, Marth C, Egle D, Galid A, Sliwa T, Lang A, Kühr T, Petzer A, Ruckser R, Greil R, Mlineritsch B, Singer CF, Seifert M, Andel J, Kwasny W, Pichler P, Tinchon C, Bartsch R. *Safety and effectiveness of nab-paclitaxel in young and elderly patients with metastatic breast cancer: A prospective, multicentre non-interventional study*. *Annals of Oncology*, Vol. 27, 2016, Supplement 6, 75, Abstract 241P (ESMO 2016)

Schlenk RF, Fiedler W, Salih HR, Wulf G, Thol F, Kündgen A, Kindler T, Salwender HJ, Lübbert M, Brossart P, Westermann J, Kraemer D, Goetze K, Horst HA, Krauter J, Girschikofsky M, Ringhoffer M, Südhoff T, Held G, Kirchner HH, Schmiegel W, Greil R, Griesshammer M, Lange E, Martens U, Hertenstein B, de Wit M, Koller E, Petzer A, Hesse T, Runde V, Reimer P, Schultheis B, Kirchen H, Griesinger F, Hebart H, Heil G, Kremers S, Nachbaur D, Basara N, Schwänen C, Schöndube D, Greiner J, Münnich A, Weber D, Gaidzik VI, Teleanu V, Paschka P, Theis F, Benner A, Heuser M, Döhner K, Ganser A, Döhner H. *Impact of Age and Midostaurin-Dose in Response and Outcome in Acute Myeloid Leukemia with FLT3-ITD: Interim-Analysis of the AMLSG 16-10 Trial*. ASH Annual Meeting 2016, Oral Presentation, Abstract #449, Session 613

Ludwig H, Gunsilius E, Fridrik M, Greil, R, Petzer A, Kühr T, Knop S, Schreder M, Rauch E, Poenisch W, Zojer N. *Ixazomib, Thalidomide and Dexamethasone (IxaThalDex) in Relapsed/Refractory Multiple Myeloma (RRMM): An Interim Analysis of a Phase II Trial.* (AGMT MM-1) ASH Annual Meeting 2016, Oral Presentation, Abstract #3335, Session 653

Rinnerthaler G, Gampenrieder SP, Voskova D, Petzer A, Hubalek M, Petru E, Hartmann B, Andel J, Balic M, Melhardt T, Ulmer H, Mlineritsch B, Greil R. *Capecitabine in combination with bendamustine in pretreated women with HER2negative metastatic breast cancer: final PFS results of a phase II trial (AMT MBC-6).* San Antonio Breast Cancer Symposium 2016, Poster Session 5, Category 15, Poster #13 (P5-15-13)

## Molekularbiologie

Webersinke G. Molecular pathogenesis of chronic myeloid leukemia *Magazine of European Medical Oncology*. 2016; doi: 10.1007/s12254-016-0294-0

Popper H.H, Gruber-Moesenbacher U, Hutarew G, Hochmair M, Absenger G, Brcic L, Müllauer L, Dekan G, Sentinek U, Krenbek D, Vesely M, Pirker R, Hilbe W, Kolb R, Webersinke G, Hernler T, Pall G, Lax S, Mohn-Stauder A. Recommendations of the Austrian Working Group on Lung Pathology and Oncology for predictive molecular and immunohistochemical testing in non-small cell lung cancer. *Magazine of European Medical Oncology*. 2016; doi:10.1007/s12254-016-0297-x

Ulz P, Belic J, Graf R., Auer M., Lafer I, Fischerder K, Webersinke G, Pummer K, Augustin H, Pichler M, Hoefler G, Bauernhofer T, Geigl J.B, Heitzer E, Speicher R.M. Whole-genome plasma sequencing reveals focal amplifications as a driving force in metastatic prostate cancer. *Nature Communications* 2016; doi: 10.1038/ncomms12008

Malli T, Buxhofer-Ausch V, Erdel M, Kranewitter W, Rumpold H, Marschon R, Deutschbauer S, Simonitsch-Klupp I, Valent P, Müllner-Ammer K, Sebesta C, Webersinke G. Functional characterization and localization of the TPR-FGFR1 fusion protein in 8p11 myeloproliferative syndrome. *Genes, Chromosomes and Cancer* 2016; 55(1):60-8.

Johansson P, Bergmann A, Rahmann S, Wohlers I, Scholtysik R, Przekowitz M, Seifert M, Tschurtschenthaler G, Webersinke G, Jäger U, Siebert R, Klein-Hitpass L, Dührsen U, Dürig J, Küppers R. Recurrent alterations of TNFAIP3 (A20) in T-cell large granular lymphocytic leukemia. *Int J Cancer* 2016; 138(1):121-4.

- **Tagungsbeiträge**

Burghofer J, Kranewitter W, Weitzendorfer M, Marschon R, Rammer M, Alibegovic V, Rumpold H, Petzer A.L, Webersinke G. Circulating cell-free DNA in tumor patients. *OeGHO Jahrestagung 2016*; Oral „Best submitted abstracts“. Posterpreis Onkologie

Rammer M, Webersinke G, Haitzchi-Petnehazy S, Bauer E, Hackl H, Charoentong P, Trajanoski Z, Malli T, Steinmair M, Petzer A.L, Rumpold H. Stage specific miRNA expression in colon cancer. *OeGHO Jahrestagung 2016*; Oral „Best submitted abstracts“

## Radioonkologie

Springer A, Hammer J, Winkler E, Track C, Huppert R, Böhm A, Kasparu H, Weltermann A, Aschauer G, Petzer AL, Putz E, Altenburger A, Gruber R, Moser K, Wiesauer K, Geinitz H. Total body irradiation with volumetric modulated arc therapy: Dosimetric data and first clinical experience. *Radiat Oncol*. 2016 Mar; 22;11:46. doi: 10.1186/s13014-016-0625-7.



Sage EK, Schmid TE, Sedelmayr M, Gehrmann M, Geinitz H, Duma MN, Combs SE, Multhoff G. Comparative analysis of the effects of radiotherapy versus radiotherapy after adjuvant chemotherapy on the composition of lymphocyte subpopulations in breast cancer patients. *Radiother Oncol.* 2016 Jan; 118(1):176-80. doi: 10.1016/j.radonc.2015.11.016.

Langsteger W, Fitz F, Rezaee A, Geinitz H, Beheshti M. Ga-PSMA PET/CT with MRI fusion: spinal cord metastasis from prostate cancer. *European Journal of Nuclear Medicine and Molecular Imaging.* 2017 Feb

Beheshti M, Rezaee A, Geinitz H, Loidl W, Pirich C, Langsteger W. Evaluation of Prostate Cancer Bone Metastases with <sup>18</sup>F-NaF and <sup>18</sup>F-Fluorocholine PET/CT. *Journal of Nuclear Medicine* 2016 Oct; 57(Suppl 3):55S-60S.

## Nuklearmedizin

Beheshti M, Rezaee A, Langsteger W. 68Ga – PSMA – HBED Uptake on Cervicothoracic (Stellate) Ganglia - A Common Pitfall on PETCT. *Clin Nucl Med IN PRESS*, 2016; IF 4,278 TOP

Langsteger W, Fitz F, Rezaee A, Geinitz H, Beheshti M. 68Ga – PSMA PET – CT with MRI Fusion: Spinal Cord Metastasis from Prostate Cancer. *EJNMMI* 44, 348-349, 2016; IF 5,537 TOP

Beheshti M, Rezaee A, Loidl W, Geinitz H, Langsteger W. Evaluation of Prostate Cancer Bone Metastases with 18F - NaF and 18F - Choline PET/CT. *J Nucl Med* 57, 55S – 60S, 2016; IF 6,381 TOP

Beheshti M, Rezaee A, Langsteger W. 18F NaF PET - CT and 99mTc - MDP Bone Scintigraphy in the Detection of Bone Metastases in Prostate Cancer. *Semin Nucl Med* 46, 491 – 501, 2016; IF 4,534 TOP

Van den Wyngart T, Strobel K, Kampen WU, Kuwert T, Van der Bruggen W, Mohan HK, Gnanasegaran G, Delgado – Bolton R, Weber WA, Beheshti M, Langsteger W, Giammarile F, Mottaghy FM, Paycha F. The EANM Practice Guidelines for Bone Scintigraphy. *EJNMMI* 43, 1723 - 1738, 2016; IF 5,537 TOP

Treglia G, Aktolun C, Chiti A, Frangos S, Giovanella L, Hoffmann M, Iakovou I, Mihailovic J, Krause BJ, Langsteger W, Verburg FA, Luster M. Editorial: The 2015 Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma: The “Evidence – Based“ Refusal to Endorse them by EANM due to the “not evidence – based“ Marginalization of the Role of Nuclear Medicine. *EJNMMI* 43, 1486 – 1490, 2016; IF 5,537 TOP

## Pathologie

Liegl-Atzwanger B, Heitzer E, Flicker K, Müller S, Ulz P, Saglam O, Tavassoli F, Devouassoux-Shisheboran M, Geigl J, Moinfar F. Exploring chromosomal abnormalities and genetic changes in uterine smooth muscle tumors. *Modern Pathology* 2016 Oct; 29(10):1262-77. Doi: 10.1038/modpathol.2016.107. PMID: 27363490

Tramm T, Kim JY, Leibl S, Moinfar F, Tavassoli FA. Expression of C-KIT, CD24, CD44s, and COX2 in benign and non-invasive apocrine lesions of the breast. *Virchows Archiv* 2016 Sep; 469(3):285-95. Doi: 10.1007/s00428-016-1966-1. PMID:27287269

Jahn SW, Kashofer K, Thüringer A, Abete L, Winter E, Eidenhammer S, Viertler C, Tavassoli F, Moinfar F. Mutation Profiling of Usual Ductal Hyperplasia of the Breast Reveals Activating Mutations Predominantly at Different Levels of the PI3K/AKT/mTOR Pathway. *American Journal of Pathology* 2016 Jan; 186(1):15-23. Doi: 10.1016/j.ajpath.2015.09.004. PMID 267 18977

## Urologie

Beheshti M, Rezaee A, Geinitz H, Loidl W, Pirich C, Langsteger W. Evaluation of Prostate Cancer Bone Metastases with 18F-NaF and 18F-Fluorocholine PET/CT. *Journal of Nuclear Medicine* 2016 Oct; 57(Suppl 3):55S-60S. PMID: 27694173

Fajkovic H, Mathieu R, Lucca I, Hiess M, Hübner N, Al Hussein Al Awamlh B, Lee R, Briganti A, Karakiewicz P, Lotan Y, Roupret M, Rink M, Kluth L, Loidl W, Seitz C, Klatter T, Kramer G, Susani M, Shariat SF. Validation of lymphovascular invasion is an independent prognostic factor for biochemical recurrence after radical prostatectomy. *Urologic Oncology*. 2016 May; 34(5):233.e1-6. doi: 10.1016/j.urolonc.2015.10.013. PMID: 26973136

Ponholzer A, Loidl W, Bektic J, Dorfinger K, Hraby S, Jeschke K, Kramer G, Krause S, Ludvik G, Remzi M, Roider M, Stoiber F. Austrian recommendations on Targeted Hormone Therapy for metastatic, castration-resistant prostate cancer. *Wiener klinische Wochenschrift* 2016 Feb; 128(3-4):156-63. doi: 10.1007/s00508-015-0945-x. PMID: 26831188

Sevcenco S, Mathieu R, Baltzer P, Klatter T, Fajkovic H, Seitz C, Karakiewicz PI, Rouprêt M, Rink M, Kluth L, Trinh QD, Loidl W, Briganti A, Scherr DS, Shariat SF. The prognostic role of preoperative serum C-reactive protein in predicting the biochemical recurrence in patients treated with radical prostatectomy. *Prostate Cancer Prostatic Dis*. 2016 Jun; 19(2):163-7. doi: 10.1038/pcan.2015.60. PMID: 26810014

De Santis M, Wiechno PJ, Bellmunt J, Lucas C, Su WC, Albiges L, Lin CC, Senkus-Konefka E, Flechon A, Mourey L, Necchi A, Loidl W, Retz MM, Vaissière N, Culine S. Vinflunine-gemcitabine versus vinflunine-carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1). *Annals of Oncology* 2016 Mar; 27(3):449-54. doi: 10.1093/annonc/mdv609. PMID: 26673352

Thomas JA, Tubaro A, Barber N, d'Ancona F, Muir G, Witzsch U, Grimm MO, Benejam J, Stolzenburg JU, Riddick A, Pahernik S, Roelink H, Ameye F, Saussine C, Bruyère F, Loidl W, Larner T, Gogoi NK, Hindley R, Muschter R, Thorpe A, Shrotri N, Graham S, Hamann M, Miller K, Schostak M, Capitán C, Knispel H, Bachmann A. A Multicenter Randomized Noninferiority Trial Comparing GreenLight-XPS Laser Vaporization of the Prostate and Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Obstruction: Two-yr Outcomes of the GOLIATH Study. *European Urology* 2016 Jan; 69(1):94-102. doi: 10.1016/j.eururo.2015.07.054. PMID: 26283011

## Sankt Josef Krankenhaus Wien

### Gesamtübersicht

Neri E, Bali MA, Ba-Ssalamah A, Boraschi P, Brancatelli G, Alves F, Grazioli L, Helmberger T, Lee JM, Manfredi R, Marti-Bonmati L, Matos C, Merkle EM, Beeck B, Schima W, Skehan S, Vilgrain V, Zech C, Bartolozzi C. ESGAR consensus statement on liver MR imaging and clinical use of liver-specific contrast agents. *European Radiology* 2016; 26: 921-931

Scharitzer M, Lenglinger J, Schima W, Weber M, Ringhofer C, Pokieser P. Comparison of videofluoroscopy and impedance planimetry for the evaluation of oesophageal stenosis: a retrospective study. *European Radiology* 2016 Aug

Schima W, Stübler J, Klaus A. Innere Hernie nach laparoskopischer Magenbypass-Operation. *Journal für Gastroenterologische und Hepatol Erkrankungen* 2016; 14(1):22-23

Schima W. Verlaufskontrolle eines serösen Zystadenoms des Pankreas. *Journal für Gastroenterologische und Hepatol Erkrankungen* 2016; 14(2):17-18

Schima W, Oswald S. Kombiniert perkutan-endoskopische Entfernung eines Choledochuskonkrementes. *Journal für Gastroenterologische und Hepatol Erkrankungen* 2016; 14(3):14-15

Schima W, Eisenhuber-Stadler E. mpMRT und MR-gezielte Biopsie bei Verdacht auf Prostatakarzinom. *krebshilfe* 2016; 11:X-XII

Schima W. 4-phasige Kontrastmittel-verstärkte MDCT zur HCC-Diagnose *Journal für Gastroenterologische und Hepatol Erkrankungen* 2016; 14(4):18-20

Zacherl J, Life-threatening complication of esophageal stenting: Failure of orotracheal intubation. *European Surgery* 2016; Suppl 1/16:S8.

Zacherl J, Albinni S, Radlspöck W, Eltschka B, Jovanovic Z. Quality of lymphadenectomy in minimally invasive hybrid Ivor Lewis esophagectomy for esophageal cancer. *European Surgery* 2016; Suppl

Zacherl J, Albinni S, Radlspöck W, Eltschka B, Jovanovic Z. Results of transoral flexible endoscopic septum division for symptomatic Zenker's diverticulum. *European Surgery* 2016

Zacherl J, Schneider F.J. How do I do it: Refluxchirurgie, How do I do it: Port a Cath Implantation. *Chirurgie* 2016

Obermayer A, Maier A, Zacherl J, Hitzl W, Steinbacher F. Lateral Fasciectomy Sparing the Superficial Peroneal Nerve with Simultaneous Mesh Graft in Non-healing Lateral Leg Ulcers of Divers Vascular Origins: Surgical Technique, Short- and Long-term Results from 44 Legs. *European Journal of Vascular and Endovascular Surgery* 2016; 52(2):225-32.

Schmidbauer U. Management der axillaren Lymphknoten beim Mammakarzinom. *Chirurgie* 2016